Algorae Pharmaceuticals Limited Stock price

Equities

1AI

AU0000296022

Biotechnology & Medical Research

Market Closed - Australian S.E. 01:10:10 2024-03-28 am EDT 5-day change 1st Jan Change
0.01 AUD 0.00% Intraday chart for Algorae Pharmaceuticals Limited +11.11% 0.00%
Sales 2022 3.4K 2.21K Sales 2023 42.02K 27.28K Capitalization 23.4M 15.2M
Net income 2022 -1M -649K Net income 2023 -2M -1.3M EV / Sales 2022 1,775 x
Net cash position 2022 4.24M 2.75M Net cash position 2023 4.11M 2.67M EV / Sales 2023 459 x
P/E ratio 2022
-3.58 x
P/E ratio 2023
-9.38 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 57.91%
More Fundamentals * Assessed data
Dynamic Chart
Algorae Pharmaceuticals Nears Launch of Drug Discovery Platform MT
Algorae Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Algorae Pharmaceuticals Considers Combination Therapy for NTCELL Trial MT
Algorae Pharmaceuticals Limited Announces Change of Company Secretary CI
Algorae Pharmaceuticals, HL Pharma Partner to Develop Cannabinoid Compound Storage and AI Platform MT
Algorae Pharmaceuticals Secures Agreement with HL Pharma MT
Algorae, Monash University Collaborate on Pre-Clinical Studies for Cardiovascular Diseases Drug; Shares Plunge 8% MT
Algorae Joins CSIRO's Next Generation AI Graduate Program with Grant Funding Participation; Shares Jump 8% MT
Algorae Pharmaceuticals Enters Partnership for Developing Drug Discovery AI Platform MT
Algorae Pharmaceuticals Limited announced that it has received AUD 0.001125 million in funding CI
Living Cell Technologies Collaborating With La Trobe University for Dementia Drug Candidate MT
Living Cell Technologies Limited has Changed its Name to Algorae Pharmaceuticals Limited CI
Living Cell Technologies Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Living Cell Technologies Files Provisional Patent Application for CBD-Combination Drug Candidate for Dementia MT
Living Cell Technologies May Change Name to Algorae Pharmaceuticals; Shares Rise 6% MT
More news
1 week+11.11%
1 month-9.09%
3 months-9.09%
6 months-33.33%
More quotes
1 week
0.01
Extreme 0.009
0.01
1 month
0.01
Extreme 0.009
0.01
Current year
0.01
Extreme 0.009
0.01
1 year
0.01
Extreme 0.008
0.02
3 years
0.00
Extreme 0.004
0.02
5 years
0.00
Extreme 0.004
0.06
10 years
0.00
Extreme 0.004
0.28
More quotes
Managers TitleAgeSince
Director of Finance/CFO - 15-12-31
Chief Tech/Sci/R&D Officer - 23-06-18
Chief Operating Officer - 21-12-12
Members of the board TitleAgeSince
Chairman 50 22-10-30
Director/Board Member 39 22-10-30
Director/Board Member 62 23-07-02
More insiders
Date Price Change Volume
24-03-28 0.01 0.00% 115 018
24-03-27 0.01 +11.11% 421,600
24-03-26 0.009 0.00% 500,933
24-03-25 0.009 0.00% 102,708
24-03-22 0.009 0.00% 1,011,011

Delayed Quote Australian S.E., March 28, 2024 at 01:10 am EDT

More quotes
Algorae Pharmaceuticals Limited, formerly Living Cell Technologies Limited, is an Australia-based pharmaceutical development company. The Company is focused on discovering and developing novel treatments for medical conditions with under met medical needs. Its programs include AlgoraeOS, Dementia and Parkinson’s. Its drug candidates include NTCELL for Parkinson’s disease and the AI-116 combination drug candidate for dementia. AlgoraeOS is a closed-loop platform, leveraging advanced computational tools to generate novel insights in-silico that are being developed to initiate or accelerate therapeutic programs. The AI-116 is a novel combination drug candidate made up of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The NTCELL is an alginate coated capsule product containing clusters of neonatal porcine choroid plexus cells that are injected into the damaged site within the brain to target the treatment of Parkinson’s disease.
More about the company
  1. Stock
  2. Equities
  3. Stock Algorae Pharmaceuticals Limited - Australian S.E.